39 Grants (Page 1 of 2)
2023
Targeting P2RX7 Signaling as a Biomarker for ADRD
Meyer, Jason SOnos, Kristen DSchulte, Michael L and Territo, Paul R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 1R21AG083791-01), $222,816USD, 2023-09-20 -- 2025-05-31
2022
Modulation of TNF╬▒ as a Treatment for Alzheimer's Disease and Related Dementia
Howell, Gareth R and Territo, Paul R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 1R21AG078575-01), $469,306USD, 2022-08-20 -- 2024-07-31
2021
Pre-Clinical Testing Core
TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 4U54AG054345-06-8273), $1,656,121USD, 2016-09-30 -- 2022-08-31
 
The IU/JAX Alzheimer's Disease Precision Models Center
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 4U54AG054345-06), $5,000,000USD, 2016-09-30 -- 2022-08-31
2020
IU/JAX/PITT MODEL-AD Center: PTC Hardware
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-05S2), $389,118USD, 2016-09-30 -- 2021-08-31
 
IU/JAX/Pitt MODEL-AD: Deep Phenotyping Metabolomics Year 1
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-05S1), $406,304USD, 2016-09-30 -- 2021-08-31
 
IU/JAX/Pitt MODEL-AD: Deep Phenotyping Proteomics Year 1
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-04S3), $410,578USD, 2016-09-30 -- 2020-08-31
 
IU/JAX/Pitt MODEL-AD: Murinizing Aducanumab
CARTER, GREGORY WHOWELL, GARETH RLAMB, BRUCE T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-04S4), $396,250USD, 2016-09-30 -- 2020-08-31
 
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA206025-06), $600,621USD, 2016-05-10 -- 2022-04-30
 
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA206025-05), $600,622USD, 2016-05-10 -- 2021-04-30
 
Pre-Clinical Testing Core
TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 5U54AG054345-05-8273), $1,430,214USD, 2016-09-30 -- 2021-08-31
 
The IU/JAX Alzheimer's Disease Precision Models Center
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 5U54AG054345-05), $6,158,485USD, 2016-09-30 -- 2021-08-31
 
The Pathogenic Role of Pb in Cerebral Amyloid Angiopathy and AD
Du, Yansheng and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 1R21AG067923-01), $251,595USD, 2020-02-01 -- 2022-11-30
2019
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA206025-04), $604,910USD, 05/10/2016 -- 04/30/2021
 
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA206025-04S2), $20,000USD, 05/10/2016 -- 04/30/2021
 
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA206025-04S1), $15,365USD, 05/10/2016 -- 04/30/2021
 
Pre-Clinical Testing Core
TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 5U54AG054345-04-8273), $1,160,721USD, 2019
 
The IU/JAX Alzheimer's Disease Precision Models Center
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 5U54AG054345-04), $5,000,000USD, 09/30/2016 -- 08/31/2021
 
The IU/JAX Alzheimer's Disease Precision Models Center: Aging
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-04S1), $475,532USD, 09/30/2016 -- 08/31/2021
 
The IU/JAX Alzheimer's Disease Precision Models Center: Diet
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-03S4), $336,657USD, 09/30/2016 -- 08/31/2021
 
The IU/JAX Alzheimer's Disease Precision Models Center: Electrophysiology
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-03S5), $222,955USD, 09/30/2016 -- 08/31/2021
 
The IU/JAX Alzheimer's Disease Precision Models Center: Microbiome
CARTER, GREGORY WHOWELL, GARETH RLamb, Bruce T and TERRITO, PAUL R
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 3U54AG054345-04S2), $189,547USD, 09/30/2016 -- 08/31/2021
2018
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA206025-03S2), $20,000USD, 05/10/2016 -- 04/30/2021
 
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA206025-03S1), $52,355USD, 05/10/2016 -- 04/30/2021
 
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
Guise, Theresa AMARKS, ANDREW R and TERRITO, PAUL R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA206025-03), $630,724USD, 05/10/2016 -- 04/30/2021